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 JOINT SYMPOSIUM: ESTRO-CIRSE: PERCUTANEOUS 
ABLATION - HOW IT CAN COMPLEMENT SURGERY AND 
RADIOTHERAPY  
  
SP-0311   
Oncology intelligence approaches: small renal tumours: is it time to 
stop watching them grow?  
A. Adam1 
1Guy's and St. Thomas' NHS Foundation Trust, Department of 
Radiology, London, United Kingdom  
 
Most small renal tumours that enhance on CT and MRI are renal cell 
carcinomas. They are usually discovered incidentally. The rate of 
detection is increasing by 3-4% per year,in parallel with the increased 
use of cross-sectional imaging. Approximately 25-30% of surgically 
removed small renal masses are benign; 55-60% are indolent renal cell 
carcinomas, and only 20-25% have potentially aggressive features, 
defined by high nuclear grade locally invasive characteristics. 
Small renal tumours are often observed rather than operated on 
immediately, because they are relatively benign, and few 
metastasize. There have been no documented reports of disease 
progression in the absence of demonstrable tumour growth. As the 
incidence of small renal tumour has increased, so has the performance 
of surgery. However,the increased rate of surgery has not been 
translated into improved survival. Therefore, it is time to reassess the 
appropriateness of extirpative surgery for these small masses. 
The policy of observing small renal tumours also has to be seriously 
questioned, because lack of growth does not implicate benignity, 70% 
of tumours grow under surveillance and 40% of patients cross over to 
resection during observation. Nephron-sparing treatment of small 
neoplasms includes partial nephrectomy, thermal ablation and 
cryotherapy. Percutaneous ablation is usually carried out under CT 
guidance.The main implications are solitary kidney, renal 
insufficiency, and multiple tumours, as surgery is particularly 
problematic in these groups of patients. Ten per cent of patients with 
solitary kidneys and chronic kidney disease who have partial 
nephrectomy, progress to renal failure. In a series of 23 tumours in 
solitary kidneys treated with radiofrequency at Guy’s and St. Thomas’ 
Hospital, London, there were four local recurrences, which were 
subsequently treated successfully. There was no significant difference 
between the baseline glomerular filtration rate and the GRF at 3, 12 
and 24 months. None of the patients required haemodialysis. 
Percutaneous cryotherapy is similarly successful, and has a very low 
recurrence rate. 
Taking into consideration the very low morbidity of percutaneous 
thermal ablation and cryotherapy, the time has probably come to 
abandon the policy of observation of small renal tumours in most 
patients with this condition.    
 
SP-0312   
Image guided percutaneous ablation of pulmonary tumors: how it 
can complement surgery and radiotherapy ?  
T. DeBaere1 
1Institut Gustave Roussy, Interventuonal Radiology, Villejuif, France  
 
Image guided percutaneous radiofrequency ablation of lung cancer is a 
thermal destruction of small primary and metastatic lung tumors. 
Since, its first use in 2000, numerous reports have demonstrated 
safety and low invasiveness of the technique, rendering possible to 
treat non surgical candidates, namely with limited pulmonary function 
or other comorbidities. Indeed, several studies have demonstrated no 
changes in respiratory function in short or long term. 
Complete ablation has been demonstrated in 100% of pathologic 
studies obtained after radiofrequency ablation of 9 lung metastases 
measuring 3cm or less. The reported local success rate of ablation is 
around 90% in a review paper, with even better results for tumor 
below 2 cm. There is no difference demonstrated in local efficacy in 
between primary NSLC and lung metastases. Overall survival of 
treated patient with NSCLC is in between 55 and 60% at 4 years in 
most recent studies. For colorectal metastasis, a 70% 3-years overall 
survival is achieved. However, even if survival data are encouraging, 
improvement of survival after thermal ablationis hard to demonstrate.  
Even if some data exists on the synergy of combination of radiation 
therapy and radiofrequency ablation, they need to be refined.  
Consequently today SBRT and thermal ablation challenge the same 
population of non-surgical candidate and data are lacking to 
demonstrate superiority of one technique over the other.  
Today both SBRT and radiofrequency ablation are limited to non-
surgical candidates. A challenge of the future is to determine a 
subpopulation of patients that can benefit from thermal ablation or 
SBRT instead of surgery, and still achieved the same survival with 
improved quality of life and lower morbidity. Patients that benefit 
today from wedge resection without lymphnode resection are 
probably the target population, including both very early stage NSCLC 
and metastases of small size. 
Combination of both SBRT and thermal ablation should be evaluated in 
tumor of larger size because size increase predictive factor of 
incomplete treatment for both SBRT and radiofrequency ablation. 
Both SBRT and thermal ablation are sharing some difficulties in follow-
up imaging because the tumor does not shrunk or disappear in the 
early stage after trea tment.Improvement in follow-up imaging are 
needed and this effort in improving imaging technique and criteria for 
response evaluation could be easily shared in between radiation 
therapist and interventional oncologists through the use of functional 
imaging.  
   
SP-0313   
Emerging techniques in treating hepatic malignancy  
R. Lencioni1 
1University of Pisa, Division of Diagnostic Imaging and Intervention, 
Pisa, Italy  
 
Surgery is the mainstay of liver cancer treatment. Resection and 
transplantation compete as the first-line option in patients with early-
stage hepatocellular carcinoma (HCC) on an intention-to-treat 
perspective, and achieve the best survival outcomes in well-selected 
candidates. RFA is the most common treatment offered to early-stage 
HCC patients who have been rejected for surgery. Recent reports on 
long-term outcomes of RFA-treated patients have shown that in 
patients with Child-Pugh class A and early-stage HCC, 5-year survival 
rates range 50-60%. Therefore, an open question is whether RFA can 
compete with surgical resection as first-line treatment. Two 
randomized controlled trials have been reported with opposite 
results. Thus, at this point there is no unequivocal data to back up 
RFA as a replacement of resection as first-line treatment for patients 
with early-stage HCC. While complete removal of neoplastic tissue 
(“R0” resection) is common after surgery for early-stage HCC, studies 
in which the pathological specimens of tumors ablated with RFA were 
analyzed have shown non-negligible rates of incomplete response. Is 
RFA the best technique for tumor ablation in 2013? Several novel 
alternate options are currently being explored. These methods – 
including microwave ablation, cryoablation, and irreversible 
electroporation (IRE) among others – claim to be able to overcome 
some of the limitations of RFA. Non-thermal techniques such as IRE 
have attracted attention, since the issues associated with perfusion-
mediated tissue cooling or heating are not relevant. Despite the 
progress in surgical and ablation techniques, the long-term prognosis 
of patients with early-stage HCC remains unsatisfactory compared 
with other common human cancers because of a high recurrence rate. 
Most resection and ablation series in the literature report a 5-year 
recurrence rate in excess of 70%, which is the main cause of death. A 
large trial in which the systemically active, molecular targeted drug 
sorafenib is used after successful resection or ablation is on-going. 
The outcomes of this trial are eagerly awaited, as it has the potential 
to establish, for the first time, an effective adjuvant regimen to 
improve recurrence-free survival. 
   
SP-0314   
Assessing outcomes in local tumour treatment. Lessons learnt from 
radiation oncology  
L. Kenny1 
1Royal Brisbane and Women's Hospital, Cancer Care Services, 
Brisbane, Australia  
 
Cancer is a major cause of death and morbidity world-wide. It often 
has a chronic course and the traditional means of treating cancer - 
surgery, radiation treatment and chemotherapy can in themselves be 
toxic and cause significant side effects both short and longterm. 
Cancer and its treatment can result not only in mortality and 
morbidity, but it imparts a great personal and societal economic 
burden. The world wide cost of cancer in 2009 was estimated to be 
US$305 billion with 53% being direct medical costs and 24% due to lost 
income(1). 
The traditional method of assessing tumour response with the RECIST 
criteria, developed initially in 2000 by the NCI, the NCIC clinical trials 
group and the EORTC, has been invaluable in producing a set of 
published rules that define whether target lesions improve (respond), 
stay the same (stable) or worsen (progressive)(2). More recently in 
some tumour sites the use of functional PET imaging has shown high 
predictive value in treatment outcome. 
To assess the holistic impact of cancer and treatment however, other 
methods of assessment are required and are of critical and at times 
perhaps of overriding importance. Assessing the overall benefit - have 
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we achieved what we set out to do, have the consequences of 
treatment been worth the outcome and is this economically viable. 
The collection of relevant data and its intelligent use is critical. Data 
that allows measurement of the impact of side effects of treatments 
both short and long term along a patients entire continuum of care, 
their global quality of life, the economic impact across the board and 
whether outcomes have influenced practice,  and policy  are all 
important. Knowing how cancer and treatment affect individuals is 
critical in trying to determine whether any intervention is effective, 
tolerable and acceptable. The Cancer Outcomes Measurement 
Working Group (COMWG) has provided a more inclusive method of 
global assessment(3). This Group describes current best practices and 
recommendations for assessing the following three outcomes across 
the continuum of care: health-related quality of life; economic 
burden; and patient satisfaction; 
The Radiation Oncology community has developed a scoring system for 
recording Common Toxicity Criteria both for acute and long term 
symptoms and collection of quality of life data in radiation oncology 
clinical trials is becoming routine(4). A number of radiation oncology 
and medical oncology trials groups have consumers involved in the 
development of trials and on the trial management committees along 
with experts in quality of life.   
For Interventional Oncology, having access to alarge and relevant data 
repository that allows for such global evaluation iscritical. Expanding 
data collection beyond the RECIST criteria to encompass themore 
global measures discussed above needs to become routine if 
interventional oncology treatments are to become incorporated into 
mainstream care, funded andvalued. 
1. Breakaway: The global burden of cancer—challenges and 
opportunities.  Economist Intelligence Unit Ltd 2009 
2. www.RECIST.com 
3. outcomes.cancer.gov/areas/assessment/comwg.html 
4. ctep.cancer.gov/reporting/ctc.html 
   
 POSTER DISCUSSION: 9: CLINICAL: BREAST  
  
PD-0315   
High precision of MRI-guided target volume delineation before 
breast-conserving surgery.  
M.D. den Hartogh1, M.E.P. Philippens1, I.E. Dam1, C.E. Kleynen1, 
J.H.A. Tersteeg1, R.M. Pijnappel2, A.N.T.J. Kotte1, M. van Vulpen1, B. 
van Asselen1, H.J.G.D. van den Bongard1 
1University Medical Center Utrecht, Department of Radiotherapy, 
Utrecht, The Netherlands  
2University Medical Center Utrecht, Department of Radiology, 
Utrecht, The Netherlands  
 
Purpose/Objective: MRI has a high sensitivity for tumor detection and 
a good correlation with histopathology findings. The precision of 
preoperative target volume delineation on newly developed 3D supine 
CE-MRI was compared to preoperative delineation on CE-CT in 
patients treated with breast-conserving therapy.  
Materials and Methods: We tested a newly developed 3D high 
resolution MRI protocol for target volume delineation in RT supine 
position in 14 cT1-2N0 patients. Gross tumor volumes (GTVs) were 
delineated by 4 experienced breast radiation oncologists, following 
written delineation instructions, on preoperative contrast-enhanced 
(CE) CT (1x1 mm2 in plane resolution, 3 mm slice thickness) and 3D 
CE-MRI (voxel size 1.2x1.2x1.2 mm3). To assess whether differences in 
GTV delineation were also clinically relevant, clinical target volumes 
(CTVs) were created by addition of a 1.5 cm margin around the tumor 
volume excluding the skin and chest wall. Interobserver variability 
(IOV) was assessed by calculating the conformity index (CI) and the 
center of mass distance (dCOM) for both the GTV and CTV in each 
patient. Tumor characteristics on CE-CT and CE-MRI were assessed 
and scored by an experienced breast radiologist.  
Results: In figure 1, target volume delineations of the 4 observers are 
shown on both preoperative CE-CT and CE-MRI in the same patient.  
The median CI of the GTV was higher on CE-MRI compared to CE-CT 
(Table 1). After expansion to the CTV, this difference in CI was no 
longer statistically significant. However, an incorrect GTV was 
delineated on CE-CT in 2/14 patients (14%) by multiple observers (1/4 
and 3/4 observers in each misdelineated patient). This resulted in 
high ranges of the CI on CE-CT. 
Tumor shapes were rated as more irregular and spiculated on CE-MRI. 
This did not result in a decreased CI on CE-MRI. A uniform volume 
expansion of GTV to CTV resulted in larger volumes on CE-MRI 
compared to CE-CT. 
No difference in median dCOM was observed between both image 
modalities. 
 
 
 
CI Conformity Index, GTV gross tumor volume, CTV clinical target 
volume, dCOM center of mass distance. Mean volume and dCOM were 
calculated per patient, median values were calculated over the 
included patient population. 
Conclusions: Preoperative target volume delineation showed a higher 
precision on 3D CE-MRI compared to CE-CT. A more irregular and 
spiculated tumor was visualized on CE-MRI without a decrease of 
interobserver agreement. Future studies will focus on using 
preoperative CE-MRI guided delineation in preoperative, as well as 
additional information in postoperative, whole or accelerated partial 
breast irradiation. 
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Forward planned intensity modulated whole breast 
hypofractionated radiotherapy: results in 500 patients 
A. Fodor1, M. Pasetti1, C. Fodor2, P. Mangili3, G. Rinaldin3, I. Dell'Oca1, 
C. Fiorino3, R. Calandrino3, A. Bolognesi1, N.G. Di Muzio1 
1San Raffaele Scientific Institute, Radiotherapy, Milano, Italy  
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Purpose/Objective: START A and START B studies have demonstrated 
a similar toxicity obtained by hypofractionation and standard 
fractionation in whole breast adjuvant radiotherapy. The aim of this 
study is the evaluation of hypofractionation effect on toxicity in our 
breast cancer patients.  
Materials and Methods: From 02/2009 to 01/2012 500 patients were 
treated with hypofractionated whole breast radiotherapy, 40 Gy/15 
fractions, delivered in 3 weeks, in our institution. Five patients had 
bilateral treatment. The median patient age was 62 yrs(28-91yrs). 
Table 1 Parameters of interobserver variability (n=14) 
 CT MRI  
 Median Range Median Range p-
value 
Mean volume 
(cm3) 
GTV  
CTV  
2.9 
54.0 
0.5 – 14.9  
30.3 –
112.8  
2.6  
60.9 
0.7 – 17.0 
34.5 –
129.4 
0.47 
0.02 
Conformity index 
GTV  
CTV  
0.52 
0.81 
0.24 – 0.67 
0.38 – 0.85 
0.60  
0.82  
0.48 – 0.74 
0.77 – 0.87 
<0.01 
0.11 
Mean dCOM (mm)  
GTV  
CTV  
1.5 
1.7 
0.6 – 39.6 
1.1 – 39.4  
1.2 
1.7 
0.5 – 2.3  
0.8 – 3.4 
0.08 
0.60 
 
 
